159 related articles for article (PubMed ID: 26466509)
1. [Brimonidine (Mirvaso), dermal use].
Van Genechten D
J Pharm Belg; 2015 Jun; (2):45-6. PubMed ID: 26466509
[No Abstract] [Full Text] [Related]
2. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
Bangsgaard N; Fischer LA; Zachariae C
Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629
[No Abstract] [Full Text] [Related]
3. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
4. Brimonidine gel (Mirvaso) for rosacea.
Med Lett Drugs Ther; 2013 Oct; 55(1427):82-3. PubMed ID: 24129112
[No Abstract] [Full Text] [Related]
5. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
Oon HH; Lim ZV
Australas J Dermatol; 2017 Feb; 58(1):63-64. PubMed ID: 26763464
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel.
Kim M; Kim J; Jeong SW; Jo H; Woo YR; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1143-1145. PubMed ID: 28500634
[TBL] [Abstract][Full Text] [Related]
7. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
8. MIRVASO (brimonidine tartrate) topical gel 0.33%.
Abramovits W; Prato A; Vincent KD; Scheinfeld N; Gupta AK
Skinmed; 2014; 12(1):41-3. PubMed ID: 24720083
[No Abstract] [Full Text] [Related]
9. Allergic contact dermatitis to topical brimonidine.
Rajagopalan A; Rajagopalan B
Australas J Dermatol; 2015 Aug; 56(3):235. PubMed ID: 26201375
[No Abstract] [Full Text] [Related]
10. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
11. OTC brimonidine (Lumify) for ocular redness.
Med Lett Drugs Ther; 2018 Oct; 60(1558):176. PubMed ID: 30335046
[No Abstract] [Full Text] [Related]
12. Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
Gerber PA
Br J Dermatol; 2016 Jun; 174(6):1422-3. PubMed ID: 26727630
[No Abstract] [Full Text] [Related]
13. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Allergic Contact Dermatitis to Topical Brimonidine Demonstrated With Patch Testing: Insights on Evaluation of Brimonidine Sensitization.
Ringuet J; Houle MC
J Cutan Med Surg; 2018; 22(6):636-638. PubMed ID: 30016883
[No Abstract] [Full Text] [Related]
15. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
16. Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea.
Werner K; Kobayashi TT
Dermatol Online J; 2015 Jan; 21(3):. PubMed ID: 25780983
[TBL] [Abstract][Full Text] [Related]
17. Rosacea First-choice treatments.
Prescrire Int; 2017 May; 26(182):126-128. PubMed ID: 30730673
[No Abstract] [Full Text] [Related]
18. Brimonidine for erythema caused by rosacea.
Drug Ther Bull; 2014 Dec; 52(12):138-40. PubMed ID: 25505014
[TBL] [Abstract][Full Text] [Related]
19. α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model.
Jung KI; Kim JH; Park CK
Eur J Pharmacol; 2015 Oct; 765():274-83. PubMed ID: 26300392
[TBL] [Abstract][Full Text] [Related]
20. Brimonidine tartrate gel plus topical steroid for the prevention of laser therapy-related postinflammatory hyperpigmentation.
Hong JY; Lee HW; Park KY; Kim BJ; Kim MN
Dermatol Ther; 2018 Sep; 31(5):e12657. PubMed ID: 30028559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
